topotecan has been researched along with Triple Negative Breast Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonzi, MC; Craparotta, I; Gariboldi, MB; Mancini, M; Monti, E; Pagin, M; Taiana, E | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Bocci, G; Di Desidero, T; Kerbel, RS; Man, S; Xu, P | 1 |
| Bhanumathi, R; Bhattacharyya, A; Gunasekaran, P; Kannan, S; Murugan, C; Rayappan, K; Shanthi, K; Sivasubramanian, S; Thangam, R; Thirumurugan, R; Vivek, R | 1 |
4 other study(ies) available for topotecan and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.
Topics: Antibodies, Monoclonal; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; MCF-7 Cells; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Topoisomerase I Inhibitors; Topotecan; Triple Negative Breast Neoplasms | 2014 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Topotecan; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy.
Topics: Acrylic Resins; Antineoplastic Combined Chemotherapy Protocols; Chitosan; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Oligopeptides; Quercetin; Silicon Dioxide; Topotecan; Triple Negative Breast Neoplasms | 2016 |